Furthermore, using the cutoff value of MIF generated by the ROC curve to predict the long-term adverse outcomes, we found that patients in the higher MIF level (≥ 143 ng/ml) subgroup had a greater incidence of MACCE in both the non-MetS and MetS groups during the 4.8-year follow-up period. Here, MIF is linked to metabolic syndrome.